Merck Jobs & Careers Search

Find your next job at Merck. Search Merck jobs from thousands of job and career search sites. A search engine for jobs with a different approach to job and career searches. In one simple search, job seekers get free access to millions of employment opportunities from thousands of websites. Find your next job at Merck today.

A Rocky Week For Abbott Labs (at Investopedia)

Johnson & Johnson pays $1B for Elan stake (AP)
Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.

Dow Watch: Overtime Play (at TheStreet.com)

At Last, a Heartening Drug Approval (at Motley Fool)

[video] 3 Stocks I Saw on TV (at TheStreet.com)

Stocks as Good as Gold (at Motley Fool)

Can We Innovate Our Way Out Of Recession? (at Forbes.com)

Fawcett's death spotlights a rare cancer (AP)
In a perverse twist of medical fate, Farrah Fawcett has become the poster girl for anal cancer, a rare disease often linked to a sexually transmitted virus.

Blood pressure drugs slow eye problems in diabetes (at Reuters)

MERCK & CO INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Pharmaceutical Dollar Rationing by Results (at Seeking Alpha)

U.S. group questions AstraZeneca's Crestor patent (Reuters)
A U.S. patent research group says it has uncovered evidence that could be used to declare AstraZeneca Plc's patent for its cholesterol fighter Crestor invalid.

U.S. group questions AstraZeneca's Crestor patent (at Reuters)

Merck invests $65 million in Puerto Rico expansion (AP)
Drugmaker Merck, Sharp & Dohme Ltd. has announced a $65 million expansion of its pharmaceutical laboratories in Puerto Rico.

Sanofi-Aventis to close some plants, restructure (AP)
French drugmaker Sanofi-Aventis SA on Tuesday announced a major corporate restructuring on the heels of new safety concerns that could hurt sales of a key drug, its once-a-day insulin Lantus.

Novavax in multi-million Spanish deal on vaccines (AP)
Vaccine developer Novavax Inc. has signed a deal with Spain's health ministry and a specialty drugmaker there to license its genetically engineered technology to produce pandemic and seasonal flu vaccines and build that country's first vaccine-making plant.

A Cocktail for Drug Investors (at Motley Fool)

Here We Go Again With Tysabri (at Motley Fool)

3 China Profit Plays (at Motley Fool)

Novavax stock soars on license deal (at bizjournals.com)

Merck's Heart Failure Failure
One of the drug industry's most renowned names is having a lot of trouble landing new drugs.

Could Merck Become Pharma's Yield King?
Analyst expects the company will boost dividend after its merger with Schering-Plough.

The Flu Vaccine Accelerator
To stop a pandemic, we need something faster than a chicken egg. VaxInnate holds out hope.

How To Maintain FDA Standards
Don't follow Marcia Angell's recommendations.

Merck, Schering Results Highlight Merger Need
Quarterly numbers show why Merck decided, after years of merger aversion, to buy Schering-Plough.

The Profit Pill
How one drug allowed Gilead Sciences to beat big pharma at its own game.

Politics Versus Economics In A Recession
Politicians like to exert their influence on the economy, but it can be tough when markets move this fast.

Obama Taps New FDA Leaders
White House seeks to bolster food and drug safety.

Relief For Roche After Genentech Deal
Shares of the Swiss drug maker rise after sealing a long-awaited takeover.

The End Of Merck
Merck's executives may have saved their company by losing what made it special.

Stocks Slip Ahead Of Treasury Auction
Street takes a beating but prepares for consumer confidence reports and a speech from Bernanke.

The Next Pharma Buyouts
Pfizer bought Wyeth; Merck nabbed Schering. Here's the next wave of possible suite mates.

Stocks Close Down On News Of Merck-Schering Deal
This is a transcript of the Market Update: Close video report.

Uncertain Street Finishes Lower
Merck-Schering Plough deal fails to boost investor confidence; Capital One cuts dividend.

Merger Talk Fails To Please Street
Stocks closed lower despite takeover talks in pharmaceutical and chemical sectors.

Battle Signs: Merck And J&J?
Merck's $41 billion takeout of Schering-Plough could cause a rift with Johnson & Johnson.

Merck Grabs Hold Of Schering
Pharmaceuticals giant scoops up company in a part-cash, part-stock deal.

Schering Deal Doesn't Lift All Ships
Market mixed as investors don't make a big deal out of a big deal.

Wall Street Gains After Schering Bid
Investors bid shares higher despite trouble in overseas banks.

Street Reacts To Merck Deal
Merck and Schering-Plough's $41 billion deal does little to boost investor sentiment.

Another Merger Of Weakness
After years of saying it wouldn't buy Schering-Plough, Merck does the obvious thing.

Pharma Pressures Unite Merck, Schering
Another big-ticket drug industry takeover deal is struck as patent deadlines near.

Four Thoughts On Merck-Schering
by Matthew Herper Merck is buying Schering-Plough for $41 billion. For a more complete take, see: Merck-Schering: Another Merger of Weakness. Here are some quick bullet points: The deal puts a capstone on Merck's proud history, in which it insisted...

The 100 Best Corporate Citizens
These businesses are setting the bar for corporate social responsibility.

The End For Genentech?
In the face of Roche's hostile bid, Genentech's executives are angling for a higher price.

Final Glance: Pharmaceuticals companies
NEW YORK (AP) - Shares of some top pharmaceuticals companies were mixed at the close of trading: 2009 07 02 18:15

Johnson & Johnson pays $1B for Elan stake
TRENTON, N.J. (AP) - Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially. 2009 07 02 18:04

Dow Watch: Overtime Play
Blue-chip stocks got getting hammered on feather-light volume heading into the July Fourth weekend. 2009 07 02 16:26

At Last, a Heartening Drug Approval
French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat. 2009 07 02 13:28

Wells Fargo Warms to Investment Banking
Wells Fargo is building out its investment banking franchise, rather than selling off or winding down some key Wachovia operations. 2009 07 02 12:05

Early Glance: Pharmaceuticals companies
NEW YORK (AP) - Shares of some top pharmaceuticals companies are down at 10 a.m.: 2009 07 02 10:35

3 Stocks I Saw on TV
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Teva Pharmaceuticals, Parexel International, and Icon, 2009 07 02 08:19

Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger

Merck & Co., Inc. Statement on Medicare Part D Assistance

Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent

Merck Prices $4.25 Billion Debt Offering

Merck to Hold Second-Quarter 2009 Sales and Earnings Conference Call on July 21

Merck Announces Third-Quarter 2009 Dividend

International Council of Nurses/ Merck Mobile Library Project: The Healing Power of Information
Many African nations lack a critical tool in the fight against AIDS, malaria and other diseases: nurses. “In our country, we should have more than 22,000 nurses, but there are only 9,000 now,” says Banda Aaron, a teacher at the Lewanika School of Nursing in Mongu, Zambia. This shortage is particularly problematic because nurses are the primary health care providers for the vast majority of Zambians.

New Jersey Performing Arts Center: The Art of Good Education
Actor and musician Terrance Kennedy can do something most teachers would never dare: Get a teenage boy to do a plie in front of his friends. “Once you create an environment of mutual respect and trust, they don’t mind the plie," Mr. Kennedy says, referring to the graceful ballet movement that’s often part of the theater and dance classes he teaches at New Jersey schools.

Building an Ethical South Africa One Step at a Time
Willem Landman , Ph.D., grew up during apartheid in South Africa, an experience that ignited a passion for justice and helped him become a powerful force for social change in his country. Today, Dr. Landman uses that same directness to build consensus and foster positive change form the inside out as chief executive officer of the Ethics Institute of South Africa (EthicSA), a non-profit organization that promotes and advances ethical practices in health care, business and government

Medical Students Fight a Silent Killer among Asian and Pacific Islanders
Steven Lin discovered his calling when his brother-in-law was diagnosed with hepatitis B at just 22. “He was healthy one day and doubled over in pain the next,” Mr. Lin, now himself 22, recalls. “At the hospital, he was told that he would likely have liver cancer by age 40. That shook my world.”

Merck Company Foundation Expands Network of Immunization Training Centers in Africa
The Merck Company Foundation announced today a $2.8 million commitment to establish two new immunization training centers in Uganda and Zambia and to expand the Foundation's support of two existing centers in Kenya and Mali as part of the Merck Vaccine Network – Africa

Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)

Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes

In Investigational Studies, New Uses of JANUVIA™ (sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes

Merck & Co., Inc. (NYSE: MRK)

Merck & Co., Inc. (NYSE: MRK) is one of the largest pharmaceutical companies in the world. The headquarters of the company is located in Whitehouse Station, NJ. It was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and set up as an independent company. It is currently one of the top 7 largest pharmaceutical companies in the world both by capital and revenue.

Merck & Co. describes itself as a "a global research-driven pharmaceutical company." Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.